Insider · CIK 0001487937
Mark Stejbach
Files at INDV (Indivior Pharmaceuticals, Inc.). First filing Jan 7, 2026, latest Jan 7, 2026.
Mark Stejbach files SEC Form 4 as director at INDV (Indivior Pharmaceuticals, Inc.). Since Jan 7, 2026, Mark Stejbach has reported 1 open-market buy worth $27k and 0 open-market sells worth $0, the latest filed on Jan 7, 2026.
A track record needs three past buys with six months of prices behind them; Mark Stejbach has 0, so none is measured yet.
The newest scored trade: bought $27k of INDV on Jan 5, 2026, filed Jan 7, 2026, scored 20 (weak), under a 10b5-1 plan. In the last 12 months: 1 buy worth $27k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
INDV: Indivior Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Indivior Pharmaceuticals, Inc. | $27k 775 shares | +5% | - |
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 26, 2026 | INDV Indivior Pharmaceuticals, Inc. | AGrant or award Common Stock | +3,722 | $0.00 | $0 | 20,569 | Jan 28, 2026 |
| Jan 5, 2026 | INDV Indivior Pharmaceuticals, Inc. | POpen-market purchase Ordinary Shares10b5-1 | +775 | $35.39 | $27k | 16,847 | Jan 7, 2026 |
Questions about Mark Stejbach
Answered from the filings on this page, as of the latest one.
Is Mark Stejbach buying or selling?
In the last 12 months Mark Stejbach reported 1 open-market buy worth $27k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $27k of INDV on Jan 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Mark Stejbach's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Mark Stejbach has 0.
Where does Mark Stejbach file Form 4?
Mark Stejbach has filed Form 4 at INDV (Indivior Pharmaceuticals, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.